Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • CLINICAL BRIEFINGS

An engineered virus shows potential as an immune therapy in glioblastoma

Therapies for aggressive, recurrent glioblastomas are sorely needed but frequently fail in trials. A first-in-human trial of CAN-3110, an engineered herpes simplex virus 1 (HSV1), shows that it is safe and seems to extend survival and stimulate immune responses — particularly in people with antibodies to HSV1.

This is a summary of: Ling, A. L. et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature https://doi.org/10.1038/s41586-023-06623-2 (2023).

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-023-02944-4

‘Expert opinion’ and the figure are published under a CC BY 4.0 licence.

References

  1. Vargas López, A. J. Neuro-oncology 23, 502–503 (2021).

    Article  Google Scholar 

  2. Chuntova, P. et al. Neuro-oncology 23, 356–375 (2021).

    Article  PubMed  Google Scholar 

  3. Peruzzi, P. & Chiocca, E. A. Nature Rev. Clin. Oncol. 15, 657–658 (2018).

    Article  PubMed  Google Scholar 

  4. Chiocca, E. A., Nakashima, H., Kasai, K., Fernandez, S. A. & Oglesbee, M. Mol. Ther. Methods Clin. Dev. 17, 871–893 (2020).

    Article  PubMed  Google Scholar 

  5. Guerra, G. et al. Neuro-oncology 25, 1047–1057 (2023).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links